From our large database of healthy normal volunteers and patients, CCT can quickly enroll almost any specified population into Phase I studies. In addition, we provide rapid regulatory turnaround and shortened IRB approval times to meet your aggressive timelines.

Additional CCT traditional Phase I service highlights include:

First in Human, Single Ascending Dose (SAD)
Our team of physicians round daily and our patients reside in a hospital environment for maximal safety and rapid response to medical emergencies. For example, when a code is called, CCT does not have to dial '9-1-1' as many of our competitors do.

First in Human and First in Patient, Multiple Ascending Dose (MAD)
CCT is able to determine a true Maximum Tolerated Dose (MTD) because we can maintain subjects on our Phase I unit for longer than 28 days, potentially necessary if the study requires dosing to steady state with a long half-life compound.

Pharmacokinetic Studies
Studies that can be conducted include bioavailability, food effects, drug-drug interactions evaluation in healthy subjects or special populations. CCT scientists and clinical researchers are recognized experts in drug-drug interactions, pharmacogenetics, and bioavailability studies.

CCT is also a recognized leader in comprehensive and definitive cardiovascular evaluation studies (i.e., QTc interval evaluations using telemetry and holter monitoring).

For all of your traditional Phase I studies needs, rely on our Early Drug Discovery unit for ongoing studies and compound development plans.